Supplementary file 1_Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.docx
Background<p>The aim of this study was to investigate the mechanism of the Poly ADP-ribose polymerase (PARP) inhibitor pamiparib (PAM) and the tyrosine kinase inhibitor anlotinib (ANL), utilizing a Biological Factor Regulatory Neural Network (BFReg-NN) and metabolomics approach.</p>Metho...
Gorde:
| Egile nagusia: | |
|---|---|
| Beste egile batzuk: | , , , , , , |
| Argitaratua: |
2025
|
| Gaiak: | |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|